Angelica Welch

Articles

Pembrolizumab Fails to Show Survival Benefit in PD-L1 ≥1 Gastric/GEJ Cancers

June 21st 2018

Second-line treatment with pembrolizumab (Keytruda) did not significantly improve overall survival or progression-free survival in patients with advanced or metastatic gastric or gastroesophageal junction cancer with a PD-L1 combined positive score ≥1.

Evolution of Genetic Testing in Breast Cancer Continues

June 21st 2018

Michael Simon, MD, MPH, discusses advances in genetic testing for breast cancer, highlighting the overlap between genomic risk assessment and tumor genomic profiling.

TAS-120 Shows Promise in Cholangiocarcinoma

June 21st 2018

TAS-120 demonstrated a clinically meaningful benefit with a manageable toxicity profile in patients with cholangiocarcinoma harboring FGFR2 gene fusions, including patients who had progressed on an FGFR inhibitor.

Upfront Duvelisib Plus FCR Shows Promise in Younger Patients With CLL

June 17th 2018

The combination of duvelisib and fludarabine-cyclophosphamide-rituximab demonstrated efficacy as a frontline treatment for younger patients with chronic lymphocytic leukemia.

Polatuzumab Vedotin Plus BR Demonstrates Higher PET-CR in DLBCL

June 16th 2018

The addition of polatuzumab vedotin to bendamustine and rituximab induced a higher rate of complete responses by PET scan compared with BR alone in patients with relapsed/refractory diffuse large B-cell lymphoma.

PET-Guided De-escalation Effective in Advanced Hodgkin Lymphoma

June 15th 2018

PET can be safely used to guide treatment in patients with untreated advanced-stage classical Hodgkin lymphoma after 2 cycles of upfront de-escalated BEACOPP.

Expert Stresses Importance of End-of-Life Care in Pediatric Oncology

June 14th 2018

Justin N. Baker, MD, discusses the benefits of a holistic approach to end-of-life care in pediatric oncology, as well as the importance of teaching palliative care to the next generation of oncologists and hematologists.

Update Sustains Liso-Cel as Strong Contender in CAR T-Cell Space

June 14th 2018

The CD19-directed chimeric antigen receptor T-cell therapy lisocabtagene maraleucel (JCAR017; liso-cel) is showing promising response rates in patients with high-risk diffuse large B-cell lymphoma.

Trastuzumab Deruxtecan Efficacious in Breast Cancer Across Varying HER2 Levels

June 13th 2018

Long-term findings from a phase I study of trastuzumab deruxtecan showed that the investigational HER2-targeting antibody-drug conjugate had antitumor activity in multiple tumor types that expressed HER2 at varying levels.

Expert Predicts the Trajectory of Biosimilars in Oncology

June 8th 2018

Haythem Y. Ali, MD, discusses the state of biosimilar development and implementation in the field of oncology.

Amid Success, Immunotherapy Faces Challenges in GI Malignancies

June 8th 2018

Gregory L. Beatty, MD, PhD, shares his insight on the challenges with sequencing immunotherapies in light of recent advancements in gastrointestinal malignancies.

Surgery Remains Vital in Hepatobiliary Neoplasms

June 8th 2018

Theodore H. Welling, MD, discusses the expanding role of surgery in hepatobiliary neoplasms.

Expert Says Paradigm Shift Imminent in SCLC

June 7th 2018

Anne Chiang, MD, PhD, discusses recent developments with immunotherapy and the overall outlook for the treatment landscape of small cell lung cancer.

CAR T-Cell Therapy Explored in Mantle Cell Lymphoma

June 7th 2018

The CD19-targeted CAR T-cell product axicabtagene ciloleucel (axi-cel; Yescarta) is currently being investigated in patients with relapsed/refractory MCL in the ongoing ZUMA-2 trial.

Ivosidenib Demonstrates Durable Responses in R/R AML

June 5th 2018

Ivosidenib induced an overall response rate of 41.6% (95% CI, 32.9-50.8) in patients with IDH1-positive relapsed/refractory acute myeloid leukemia.

Once Weekly Carfilzomib Superior in Relapsed/Refractory Myeloma

June 2nd 2018

Carfilzomib (Kyprolis) administered once weekly at 70 mg/m2 with dexamethasone resulted in a prolonged PFS compared with the standard twice-weekly schedule in patients with relapsed/refractory multiple myeloma.

Nanus Discusses Importance of Neoadjuvant and Adjuvant Care in RCC

May 30th 2018

David M. Nanus, MD, discusses the promise of immunotherapy and the continued role of surgery in the treatment in renal cell carcinoma.

Lead Investigator Discusses Tazemetostat Data in INI1-Negative Pediatric Tumors

May 30th 2018

Susan N. Chi, MD, discusses the rationale for using tazemetostat in pediatric patients with INI1-negative rhabdoid tumors, as well as the future steps being taken with this treatment.

COG Addresses Unmet Needs in Pediatric NHL

May 25th 2018

Birte Wistinghausen, MD, shares her insight on the potential for targeted therapies in the treatment of pediatric non-Hodgkin lymphoma, and the steps that the Children’s Oncology Group is taking to cure all patients with this disease.

Expert Recaps Adjuvant Advancements in HER2+ Breast Cancer

May 24th 2018

Haythem Y. Ali, MD, discusses adjuvant advances in HER2-postitive breast cancer and emerging agents in the field.

NEXT PAGE
PREVIOUS PAGE